Paloma Sosa‐Fajardo

Hypofractionation in Unresectable Stage II-III NSCLC: A Systematic Technical Review and Practical Recommendations

Background: Concurrent chemoradiotherapy (cCRT) followed by 1 year of consolidation durvalumab remains the standard of care for unresectable stage III non-small cell lung cancer (NSCLC), yet long-term survival is still limited and around 20% of patients present locoregional relap...